The core strength of our Biologics division is the ability to develop biosimilar products from the cloning stage, covering all aspects of development including establishing biosimilarity in quality, safety & efficacy.

The current Biologics portfolio comprises of 8 biosimilars. Two of our biosimilars, Teriparatide and Somatropin have received marketing authorization in India. Filgrastim and Pegfilgrastim are under late stage development.

Read more...

Molecular Biology
Construction of novel procaryotic expression vectors for higher yields and generation...

Read more...
Fermentation
Development of E. coli and yeast fermentation processes for recombinant...

Read more...
Downstream Processing
Development of process-
es for purification of recombinant proteins from...

Read more...
Bioassay / Immunoassay
Development of in vitro cell-based bio-assays for recombinant proteins and synthetic peptides...

Read more...
Analytical Development
Characterization of Proteins and Peptides by charge, mass, molecular weight, HPLC...

Read more...